- Home
- SNCY vs ABUS Comparison
SNCY vs ABUS Comparison
Compare SNCY & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNCY | ABUS |
|---|---|---|
| Founded | 1982 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.5M | 888.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNCY | ABUS |
|---|---|---|
| Price | $17.72 | $4.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $19.43 | $5.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.6M |
| Earning Date | 02-02-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.51 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $1,106,213,000.00 | $14,606,000.00 |
| Revenue This Year | $6.16 | $125.30 |
| Revenue Next Year | $8.49 | N/A |
| P/E Ratio | $16.87 | ★ N/A |
| Revenue Growth | 4.27 | ★ 116.64 |
| 52 Week Low | $8.10 | $2.71 |
| 52 Week High | $18.59 | $5.10 |
Technical Indicators
Market Signals| Indicator | SNCY | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 78.16 | 35.17 |
| Support Level | $16.81 | $4.39 |
| Resistance Level | $17.92 | $4.86 |
| Average True Range (ATR) | 0.62 | 0.25 |
| MACD | 0.23 | -0.05 |
| Stochastic Oscillator | 94.72 | 27.01 |
Price Performance
Historical ComparisonAbout SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.